Cite
HARVARD Citation
Malorni, L. et al. (2018). Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. Annals of oncology. pp. 1748-1754. [Online].